GeoVax Labs, Inc. (GOVX) Stock

GeoVax Labs, Inc. (GOVX) is a Healthcare stock trading at $1.13 (as of 2026-07-13), with a market capitalization of $8.33M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancers using a modified vaccinia Ankara virus-like particle platform. Its pipeline includes preventive candidates for targets such as COVID-19, HIV, Zika, malaria, and certain hemorrhagic fever viruses, along with therapeutic approaches for HIV and chronic hepatitis B and solid tumor cancers.

Understand GeoVax Labs, Inc.: how it makes money

GeoVax Labs is a clinical-stage biotechnology company developing human vaccines and immunotherapies for infectious diseases and cancers, using its modified vaccinia ankara virus-like particle vaccine platform, and it also works through collaboration and partnership agreements such as with the National Institute of Allergy and Infectious Diseases.

As a clinical-stage vaccine and immunotherapy developer, GeoVax's profit model is primarily tied to how its development programs progress and how well it can leverage collaborations and partnerships, rather than near-term product sales (based on the provided description).

Business quality (Weak): Limited company-specific operating KPIs and segment disclosures were provided, so the key drivers investors can monitor from the provided dataset are constrained.

Bull case

  • Broad vaccine and immunotherapy pipeline using a single platform: It is developing preventive vaccines for multiple infectious diseases (such as COVID-19, HIV, Zika virus, malaria, and hemorrhagic fever viruses including Ebola, Sudan, Marburg, and Lassa) and therapeutic vaccines for HIV, chronic Hepatitis B, and solid tumor cancers.
  • Collaboration and partnership activity: The company has collaboration and partnership agreements, including with the National Institute of Allergy and Infectious Diseases (NIAID), which can support program advancement.

Bear case

  • Financial losses are substantial in the provided quarter: For the period ending 2025-06-30, the provided operating margin is -635.8, which is consistent with significant operating losses.
  • Early-stage execution risk: Because GeoVax is described as a clinical-stage biotechnology company developing vaccines and immunotherapies, outcomes depend on development progress that can be uncertain.
Valuation — source: SEC EDGAR (first-party)
Price$1.13
Market Cap$8.33M
Price / Book4.73
FCF Yield-370.0%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$2.49M
Net Margin-862.3%
Revenue Growth (YoY)-37.1%
EPS Growth (YoY)364.7%
FCF Growth (YoY)-12.9%
Financial Health — source: SEC EDGAR
Altman Z-Score-42.74 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderARMISTICE CAPITAL, LLC ($371569.00)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEODavid Alan Dodd
Employees17
CountryUS
IPO Date2020-09-25

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Adial Pharmaceuticals, Inc. (ADIL)
  • Imunon, Inc. (IMNN)
  • Traws Pharma, Inc. (TRAW)
  • CNS Pharmaceuticals, Inc. (CNSP)
  • Soligenix, Inc. (SNGX)
  • Exicure, Inc. (XCUR)
  • Azitra, Inc. (AZTR)
  • Kairos Pharma, Ltd. (KAPA)
GOVX earnings history · GOVX institutional & insider holders · GOVX KPIs & operating metrics · GOVX financials · GOVX investor presentations & press releases · GOVX SEC filings · GOVX peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-07-13.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.